An In-depth Analysis of India's API Import Trends in Year 2022-23: Focus on the Top 10 Non-Chinese Sources

Background: India and China are pivotal players in the global Active Pharmaceutical Ingredient (API) market, and their interdependence is evident through intricate import-export dynamics within the sector. However, this symbiotic relationship faces stiff competition from counterparts in Europe, the USA, and LATAM. Specific factors drive India's procurement of certain APIs from nations beyond China, significantly impacting the economic landscape of Southern Asia. Interpreting these factors that influence import trends in the API market is necessary to strategize the future API demand-supply. Objective: This review focuses on the top 10 API imports into India in the year 2022-23 from countries other than China. The aim is to provide a comprehensive understanding of these crucial pharmaceutical components, including their applications, mode of action, and industrial synthesis processes. The review also seeks to illuminate diversification initiatives within India's API sector and unravel the reasons behind substantial import trends for each specific API. Methods: The process of data collection and its subsequent utilization in analyzing the specific surge in API imports in India during the period of 2020-2022 has been done by five distinct subprocesses: (a) data repossession and preprocessing; (b) development analysis of article publications; (c) distribution analysis of articles by subject, country, application, mode of action and synthesis; (d) scientific teamwork analysis among authors; and (e) development and discovery analysis of research topics. In the review, for each API, a framework has been provided that includes application information, synthesis with reaction scheme, price structure, and the reasons for the high import demand. Results: The escalation of import volumes of specific Active Pharmaceutical Ingredients (APIs) into India from sources outside of China can be attributed to several key factors. Among these are the implementation of revised Indian internal policies, approval for drug formulation by authorized agencies, a heightened reliance on bio-enzymatic API synthesis processes within Europe in contrast to China, the establishment of new research centers in India, and a notable surge in the incidence of certain diseases within the country. Additionally, India's burgeoning population, coupled with increased consumption of animal-derived food products, has contributed to heightened demand for APIs sourced from alternative markets than the Chinese market. These factors collectively underscore the complexity of the pharmaceutical supply chain and the various influences driving import dynamics within the Indian market. Conclusion: A thorough examination of API imports into India during the fiscal year 2022-23 has unveiled significant trends, applications, and underlying rationales driving import patterns. The consolidation of manufacturing processes has provided invaluable insights into the synthetic research pathways associated with each API listed. The data serves as a critical resource for stakeholders within the pharmaceutical sector, facilitating informed strategic decision-making and fostering advancements in India's API industry.